Trial Profile
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary) ; Paclitaxel (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms GC-MEDIOLAPAC
- 17 Apr 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 17 Apr 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 10 Apr 2023 Planned End Date changed from 30 Apr 2022 to 31 Dec 2023.